ArticleActa pharmacologica Sinica2022

Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.

Ke Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.